Research ExplorerPublicationsAutologous stem cell transplantation for therapy-related acu...

Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.

Standard

Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. / Kröger, Nicolaus; Brand, R; van Biezen, A; Cahn, J-Y; Slavin, S; Blaise, D; Sierra, J; Zander, Axel R.; Niederwieser, D; de Witte, T.

In: BONE MARROW TRANSPL, Vol. 37, No. 2, 2, 2006, p. 183-189.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Kröger, N, Brand, R, van Biezen, A, Cahn, J-Y, Slavin, S, Blaise, D, Sierra, J, Zander, AR, Niederwieser, D & de Witte, T 2006, 'Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.', BONE MARROW TRANSPL, vol. 37, no. 2, 2, pp. 183-189. <http://www.ncbi.nlm.nih.gov/pubmed/16299545?dopt=Citation>

APA

Kröger, N., Brand, R., van Biezen, A., Cahn, J-Y., Slavin, S., Blaise, D., Sierra, J., Zander, A. R., Niederwieser, D., & de Witte, T. (2006). Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. BONE MARROW TRANSPL, 37(2), 183-189. [2]. http://www.ncbi.nlm.nih.gov/pubmed/16299545?dopt=Citation

Vancouver

Kröger N, Brand R, van Biezen A, Cahn J-Y, Slavin S, Blaise D et al. Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome. BONE MARROW TRANSPL. 2006;37(2):183-189. 2.

Bibtex

@article{1d38db06bd4c421ca268a57cc369def3,
title = "Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.",
abstract = "We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT. The median age was 39 years (range, 3-69), and stem cell source was bone marrow (n = 31), or peripheral blood progenitor cells (n = 30), or the combination of both (n = 4). The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3). The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or AML (n = 56; 87%). The median time between diagnosis and transplantation was 5 months (range, 3-86). The Kaplan-Meier estimates of the probability of 3-year overall and disease-free survival were 35% (95% CI: 21-49%) and 32% (95% CI: 18-45%), respectively. The median leukocyte engraftment was faster after transplantation with peripheral blood stem cells than with bone marrow: 12 (range, 9-26) vs 29 (range, 11-67) days (P",
author = "Nicolaus Kr{\"o}ger and R Brand and {van Biezen}, A and J-Y Cahn and S Slavin and D Blaise and J Sierra and Zander, {Axel R.} and D Niederwieser and {de Witte}, T",
year = "2006",
language = "Deutsch",
volume = "37",
pages = "183--189",
journal = "BONE MARROW TRANSPL",
issn = "0268-3369",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Autologous stem cell transplantation for therapy-related acute myeloid leukemia and myelodysplastic syndrome.

AU - Kröger, Nicolaus

AU - Brand, R

AU - van Biezen, A

AU - Cahn, J-Y

AU - Slavin, S

AU - Blaise, D

AU - Sierra, J

AU - Zander, Axel R.

AU - Niederwieser, D

AU - de Witte, T

PY - 2006

Y1 - 2006

N2 - We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT. The median age was 39 years (range, 3-69), and stem cell source was bone marrow (n = 31), or peripheral blood progenitor cells (n = 30), or the combination of both (n = 4). The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3). The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or AML (n = 56; 87%). The median time between diagnosis and transplantation was 5 months (range, 3-86). The Kaplan-Meier estimates of the probability of 3-year overall and disease-free survival were 35% (95% CI: 21-49%) and 32% (95% CI: 18-45%), respectively. The median leukocyte engraftment was faster after transplantation with peripheral blood stem cells than with bone marrow: 12 (range, 9-26) vs 29 (range, 11-67) days (P

AB - We report the results of 65 patients with treatment-related myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) who were transplanted from an autograft and reported to the EBMT. The median age was 39 years (range, 3-69), and stem cell source was bone marrow (n = 31), or peripheral blood progenitor cells (n = 30), or the combination of both (n = 4). The primary disease was solid tumors (n = 37), Hodgkin's disease (n = 13), non-Hodgkin's lymphoma (n = 10), acute lymphoblastic leukemia (n = 2) or myeloproliferative syndromes (n = 3). The types of MDS were as follows: RAEB (n = 1; 2%), RAEB-t (n = 3; 5%), or AML (n = 56; 87%). The median time between diagnosis and transplantation was 5 months (range, 3-86). The Kaplan-Meier estimates of the probability of 3-year overall and disease-free survival were 35% (95% CI: 21-49%) and 32% (95% CI: 18-45%), respectively. The median leukocyte engraftment was faster after transplantation with peripheral blood stem cells than with bone marrow: 12 (range, 9-26) vs 29 (range, 11-67) days (P

M3 - SCORING: Zeitschriftenaufsatz

VL - 37

SP - 183

EP - 189

JO - BONE MARROW TRANSPL

JF - BONE MARROW TRANSPL

SN - 0268-3369

IS - 2

M1 - 2

ER -